Huntingdon, UK 4/23/08—NextGen Sciences has announced that it plans to divest or dissolve its software and instrumentation business and its protein production business within the next six months. The company intends to focus on its life science–research service business, particularly biomarker services. The company also plans to move its headquarters to the US.
This month, the markets were extremely resilient, as they shrugged off profuse negative economic data to finish the month in positive territory. For the first time since October 2007, the Dow Jones Industrial Average, S&P 500 and NASDAQ all finished higher, improving 4.5%, 4.8% and 5.9%, respectively. Investors seemed primarily focused on several positive earnings […]
Billerica, MA 4/21/08—Bruker has announced it will incur approximately $12 million in pretax foreign exchanges losses in the first quarter, which are forecasted to reduce EPS by approximately $0.06 cents after tax. The company attributed the losses to the weakening of the US dollar and an unexpected strengthening of the Swiss Franc in the five […]
Company Announcements In January, WaferGen Biosystems formally opened its Malaysian subsidiary in Kedah, which will initially focus on R&D. WaferGen also entered into a contract manufacturing agreement with Malaysia-based Pentamaster. Cepheid appointed Andrew D. Miller as senior vice president, CFO in April. He was previously vice president and chief accounting officer for Autodesk. EnviroLogix and […]
Brazil: From 2000 to 2006, the Brazilian government’s investment in nanotechnology research amounted to BRL 170.2 million ($81.5 million). Current funding includes BRL 58.6 million for the 2005–2009 National Nanotechnology Program and BRL 215 million for Millennium institutes and microelectronics research. Nanotech research in Brazil is almost entirely publicly funded and is organized by networks […]
India: India’s clinical trials and research market is expected to increase to $1.5–$2 billion by 2010. In 2006, the market grew over 65%, and is currently worth approximately $300 million. Of the 139 clinical trials outsourced to the country, GlaxoSmithKline and Johnson&Johnson outsourced 22 trials each, Eli Lilly and Bristol-Myers Squibb outsourced 17 each, and […]
Government: The US government’s expansion of DNA collection to include everyone arrested for violation of a federal law is expected to further burden federal labs. One million additional profiles are expected to be added as a result. In response, the FBI has allocated an extra $2 million to its budget. State labs have also been […]
Ludwigshafen and Heidelberg, Germany 4/3/08—Chemical firm BASF SE has acquired a 75% stake plus one share in hte AG, a provider of high-throughput experimentation products and services for catalysis, material science and formulations. Hte’s owners included private equity firms 3i Group. Financial details were not disclosed. BASF previously owned 12.7% of the company, in which […]
Company Announcements Luminex and Tyson Foods are collaborating to develop food-safety and animal-health tests. In February, Invitrogen expanded its license and supply agreement with Luminex, extending the lifetime of the license and providing it with access to next-generation multiplex detection platforms. Invitrogen offers more than 200 assays based on Luminex’s xMAP Technology. In February, Sigma-Aldrich […]
Before the digital and automation age, cell counting was performed by using a microscope paired with a hemocytometer. While this decades-old manual method is still being utilized by labs, the primary advantage of this technique is its low cost. Its many drawbacks include a lack of precision, low accuracy, lot-to-lot variability and labor intensiveness. In […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
